热门资讯> 正文
Edwards Lifesciences 2026年每股收益指导范围包含共识
2025-12-04 23:07
- 爱德华生命科学(EW) 0
- Transcat(TRNS) 0
- 波音(BA) 0
- Edwards Lifesciences (EW) newly projected 2026 adjusted EPS guidance of $2.80-$2.95 includes to consensus figure of $2.86.
- The maker of products to treat advanced cardiovascular diseases also sees constant currency sales growth of 8%-10% next year.
- Transcatheter aortic valve replacement (TAVR) is projected at $4.6B-$4.9B; surgical sales at $1.05B-$1.13B; and sales of transcatheter mitral and tricuspid therapies (TMTT) of $740M-$780M.
- Edwards added it sees TMTT sales reaching $2B by 2030.
- The company also reaffirmed its 2025 adjusted EPS guidance of $2.56-$2.62. Consensus is $2.59.
More on Edwards Lifesciences
- Edwards Lifesciences Corporation (EW) Q3 2025 Earnings Call Transcript
- Edwards Lifesciences: Inflection Incoming, But When?
- Notable analyst calls this week: Meta, Boeing and Comcast among top picks
- Edwards Lifesciences trading flat despite 2025 guidance raise, Q3 beats
- Seeking Alpha’s Quant Rating on Edwards Lifesciences
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
